WuXi AppTec Co Ltd - Asset Resilience Ratio
WuXi AppTec Co Ltd (603259) has an Asset Resilience Ratio of 3.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how WuXi AppTec Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down WuXi AppTec Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.94 Billion | 3.51% |
| Total Liquid Assets | CN¥2.94 Billion | 3.51% |
Asset Resilience Insights
- Limited Liquidity: WuXi AppTec Co Ltd maintains only 3.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
WuXi AppTec Co Ltd Industry Peers by Asset Resilience Ratio
Compare WuXi AppTec Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Predilife SA
F:0GA |
Diagnostics & Research | 17.69% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
Annual Asset Resilience Ratio for WuXi AppTec Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for WuXi AppTec Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.54% | CN¥1.23 Billion | CN¥80.33 Billion | +0.47pp |
| 2023-12-31 | 1.07% | CN¥785.78 Million | CN¥73.67 Billion | +1.06pp |
| 2022-12-31 | 0.00% | CN¥2.00 Million | CN¥64.69 Billion | -0.95pp |
| 2021-12-31 | 0.96% | CN¥527.29 Million | CN¥55.13 Billion | -9.02pp |
| 2020-12-31 | 9.98% | CN¥4.62 Billion | CN¥46.29 Billion | +4.16pp |
| 2019-12-31 | 5.82% | CN¥1.70 Billion | CN¥29.24 Billion | -3.56pp |
| 2018-12-31 | 9.38% | CN¥2.13 Billion | CN¥22.67 Billion | +9.26pp |
| 2017-12-31 | 0.12% | CN¥14.74 Million | CN¥12.58 Billion | -3.98pp |
| 2016-12-31 | 4.10% | CN¥434.19 Million | CN¥10.59 Billion | +1.10pp |
| 2015-12-31 | 3.00% | CN¥290.84 Million | CN¥9.69 Billion | -3.25pp |
| 2014-12-31 | 6.25% | CN¥472.59 Million | CN¥7.56 Billion | -- |
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more